Ikarian Capital’s Seres Therapeutics MCRB Stock Holding History

Ikarian Capital’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-17,615	Closed	-$1.68M	–	198
2020 Q2	$1.68M	Buy	+17,615	New	+$1.55M	0.13%	113

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital's MCRB Position: Q4 2022 in Review

Ikarian Capital sold out of Seres Therapeutics (MCRB) in Q4 2022, closing a stake of 6,566 shares — an estimated $843K sold.

Ikarian Capital first reported a position in MCRB in Q3 2020 and held it in 7 quarters. The position peaked at $7.21M in Q1 2021. 123 funds tracked by Wall St. Rank hold MCRB as of Q4 2022.

Ikarian Capital reported no remaining Seres Therapeutics position as of Q4 2022 after selling out during the quarter.
Ikarian Capital sold 6,566 Seres Therapeutics shares in Q4 2022, an estimated $843K.
Ikarian Capital first reported a position in Seres Therapeutics in Q3 2020 and held it in 7 quarters.
Ikarian Capital's Seres Therapeutics position peaked at $7.21M in Q1 2021.
123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2022.

Based on Ikarian Capital's 13F filing for Q4 2022, filed 14 Feb 2023.